Denise K Walters

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes
    Denise K Walters
    Department of Hematology and Oncology, Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, 3181 Sam Jackson Park Road, and Portland VA Medical Center, Portland, OR 97239, USA
    Leuk Res 30:1097-104. 2006
  2. ncbi RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518
    Denise K Walters
    Department of Hematology and Oncology, Howard Hughes Medical Institute, Oregon Health and Science University, and Portland Veterans Affairs VA Medical Center, 3181 Sam Jackson Park Rd, Portland, OR 97239, USA
    Blood 105:2952-4. 2005
  3. ncbi Activating alleles of JAK3 in acute megakaryoblastic leukemia
    Denise K Walters
    Howard Hughes Medical Institute, Portland, Oregon 97239, USA
    Cancer Cell 10:65-75. 2006
  4. ncbi Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib
    Thomas O'Hare
    Howard Hughes Medical Institute, Oregon Health and Science University, Portland 97239, USA
    Clin Cancer Res 11:6987-93. 2005
  5. ncbi RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, USA
    Blood 111:2238-45. 2008
  6. ncbi In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    Thomas O'Hare
    Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland 97239, USA
    Cancer Res 65:4500-5. 2005
  7. ncbi AMN107: tightening the grip of imatinib
    Denise K Walters
    Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland, Oregon, 97239, USA
    Cancer Cell 7:117-9. 2005
  8. ncbi Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia
    Ting Lei Gu
    Cell Signaling Technology, Inc, 3 Trask Lane, Danvers, MA 01923, USA
    Blood 108:4202-4. 2006
  9. ncbi Transactivation of gp130 in myeloma cells
    Jena D French
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 170:3717-23. 2003
  10. ncbi Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex
    Denise K Walters
    Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Oncogene 22:3598-607. 2003

Detail Information

Publications14

  1. ncbi Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes
    Denise K Walters
    Department of Hematology and Oncology, Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, 3181 Sam Jackson Park Road, and Portland VA Medical Center, Portland, OR 97239, USA
    Leuk Res 30:1097-104. 2006
    ..This study illustrates the benefit of LC-MS/MS mass spectrometry and siRNA for the identification of novel targets and mutations...
  2. ncbi RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518
    Denise K Walters
    Department of Hematology and Oncology, Howard Hughes Medical Institute, Oregon Health and Science University, and Portland Veterans Affairs VA Medical Center, 3181 Sam Jackson Park Rd, Portland, OR 97239, USA
    Blood 105:2952-4. 2005
    ..Furthermore, siRNA-induced down-regulation of FLT3 increased the sensitivity of both cell lines to treatment with the FLT3 inhibitor MLN518. This illustrates the potential benefit of combined therapeutic approaches...
  3. ncbi Activating alleles of JAK3 in acute megakaryoblastic leukemia
    Denise K Walters
    Howard Hughes Medical Institute, Portland, Oregon 97239, USA
    Cancer Cell 10:65-75. 2006
    ..These findings illustrate the biological importance of gain-of-function JAK3 mutations in leukemogenesis and demonstrate the utility of proteomic approaches to identifying clinically relevant mutations...
  4. ncbi Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib
    Thomas O'Hare
    Howard Hughes Medical Institute, Oregon Health and Science University, Portland 97239, USA
    Clin Cancer Res 11:6987-93. 2005
    ..As combination therapy is frequently used to prevent emergence of resistance, the combination of imatinib with an inhibitor of imatinib-resistant Bcr-Abl mutants (e.g., Src/Abl inhibitors AP23848 and BMS-354825) was investigated...
  5. ncbi RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, USA
    Blood 111:2238-45. 2008
    ..This technique, with additional development, might eventually offer the potential to match specific therapies with individual patients based on a functional assay...
  6. ncbi In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    Thomas O'Hare
    Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland 97239, USA
    Cancer Res 65:4500-5. 2005
    ..Thus, both inhibitors hold promise for treating imatinib-refractory CML...
  7. ncbi AMN107: tightening the grip of imatinib
    Denise K Walters
    Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland, Oregon, 97239, USA
    Cancer Cell 7:117-9. 2005
    ..The implications of these results, and the potential role this and other novel ABL inhibitors may have in treating patients with CML, are discussed...
  8. ncbi Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia
    Ting Lei Gu
    Cell Signaling Technology, Inc, 3 Trask Lane, Danvers, MA 01923, USA
    Blood 108:4202-4. 2006
    ..Thus, the KG-1 cell line provides an in vitro model for the study of FGFR1 fusions associated with leukemia and for the analysis of small molecule inhibitors against FGFR1 fusions...
  9. ncbi Transactivation of gp130 in myeloma cells
    Jena D French
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 170:3717-23. 2003
    ..Finally, transactivation of gp130 may be a common theme in myeloma cells, perhaps providing a mechanism for enhanced or qualitatively distinct cellular responses to specific stimuli...
  10. ncbi Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex
    Denise K Walters
    Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Oncogene 22:3598-607. 2003
    ..These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor...
  11. ncbi A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells
    Denise K Walters
    Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Oncogene 23:1197-205. 2004
    ..These findings validate our previous report of ErbB3 involvement in IFN-alpha-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system...
  12. ncbi A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia
    Ting Lei Gu
    Cell Signaling Technology, Danvers, MA 01923, USA
    Blood 110:323-33. 2007
    ..These findings identify a novel potential therapeutic target in leukemogenesis, and demonstrate the utility of phosphoproteomic strategies for discovery of tyrosine kinase alleles...
  13. ncbi Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines
    Denise K Walters
    Laboratory for Orthopaedic Research, Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Forchstrasse 340, 8008 Zurich, Switzerland
    Invest New Drugs 25:305-12. 2007
    ..These data indicate that taurolidine possesses potent anti-neoplastic activity against osteosarcoma cell lines and may have potential as a novel OS chemotherapeutic agent...
  14. ncbi Cytotoxic effects of curcumin on osteosarcoma cell lines
    Denise K Walters
    Laboratory for Orthopaedic Research, Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Forchstrasse 340, 8008 Zurich, Switzerland
    Invest New Drugs 26:289-97. 2008
    ..These data indicate that the potent cytotoxic activity of curcumin on OS cell lines is mediated by induction of apoptotic processes. Thus, curcumin has potential to be a novel OS chemotherapeutic agent...